PriceTargets.com logo

NASDAQ:NPCE - NeuroPace Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.00
  • Forecasted Upside: 13.54 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$23.78 As of 06/18/2021 01:00 AM ET
▼ -0.29 (-1.20%)
1 month | 3 months | 12 months
Get New NeuroPace Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NPCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NPCE

Average Price Target: $27.00
▲ +13.54% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for NeuroPace in the last 3 months. The average price target is $27.00, with a high forecast of $30.00 and a low forecast of $25.00. The average price target represents a 13.54% upside from the last price of $23.78.

Buy

The current consensus among 4 investment analysts is to buy stock in NeuroPace.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2021SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $30.00Low
5/17/2021SVB LeerinkInitiated CoverageOutperform$25.00Medium
5/17/2021Wells Fargo & CompanyInitiated CoverageOverweight$25.00Medium
5/17/2021JPMorgan Chase & Co.Initiated CoverageOverweight$27.00Medium
5/17/2021Morgan StanleyInitiated CoverageOverweight$26.00Medium
(Data available from 6/18/2016 forward)
NeuroPace logo
NeuroPace, Inc. operates as a medical device company in the United States. The company develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. Its RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $23.78
Low: $23.16
High: $24.76

50 Day Range

MA: N/A

52 Week Range

Now: $23.78
Low: $18.24
High: $27.38

Volume

400,189 shs

Average Volume

155,880 shs

Market Capitalization

$577.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuroPace?

The following Wall Street analysts have issued stock ratings on NeuroPace in the last year: JPMorgan Chase & Co., Morgan Stanley, SVB Leerink LLC, and Wells Fargo & Company.
View the latest analyst ratings for NPCE.

What is the current price target for NeuroPace?

4 Wall Street analysts have set twelve-month price targets for NeuroPace in the last year. Their average twelve-month price target is $27.00, suggesting a possible upside of 9.3%. SVB Leerink LLC has the highest price target set, predicting NPCE will reach $30.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $25.00 for NeuroPace in the next year.
View the latest price targets for NPCE.

What is the current consensus analyst rating for NeuroPace?

NeuroPace currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NPCE will outperform the market and that investors should add to their positions of NeuroPace.
View the latest ratings for NPCE.

What other companies compete with NeuroPace?

Other companies that are similar to NeuroPace include Aveanna Healthcare, Instil Bio, ModivCare, Global Blood Therapeutics, Centessa Pharmaceuticals, Outset Medical, Rubius Therapeutics, Hims & Hers Health, bluebird bio, MorphoSys, Aurora Cannabis, Revance Therapeutics, Fulgent Genetics, Bionano Genomics and Nuvation Bio.

How do I contact NeuroPace's investor relations team?

The company's listed phone number is 650-237-2700. The official website for NeuroPace is www.neuropace.com.